Navigation Links
OncoGenex Reports First Quarter Financial Results
Date:5/7/2009

ogenex.com" target="_new">www.oncogenex.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning the Company's key objectives for 2009, and other anticipated activities, achievements, occurrences and performance. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements.

The potential risks and uncertainties associated with forward-looking statements include, among others, the timing and costs of clinical trials and regulatory approvals, risks that clinical trials will not be successful or confirm earlier or interim clinical trial results, the Company's need for additional financing, the uncertainty associated with any potential partnering discussions, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal year 2008 and its Quarterly Report for the first quarter of 2009 on Form 10-Q. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or that if any of them do transpire or occur, what impact they would have on the results of operations or financial condition of the Company. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.

    Condensed Consolidated Stat
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
2. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
3. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
4. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
5. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
6. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
7. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
8. OncoGenex Reports Third Quarter Financial Results
9. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Memphis, TENN (PRWEB) December 22, 2014 ... with Donor Egg Bank USA , a network ... the country. Through this partnership, patients have fast access ... for in vitro fertilization, IVF . Fertility Associates of ... to offer this fertility treatment option. , Dr. ...
(Date:12/19/2014)... Charm Sciences is pleased to announce that its ... M1 in raw commingled milk is the first lateral ... peer reviewed report of the validation by Technology and ... Fisheries Research (ILVO-T&V) has been published by the Taylor ... toxic aflatoxin and a known carcinogen, can be passed ...
(Date:12/19/2014)... 19, 2014 Naurex Inc., a biopharmaceutical company ... diseases of the central nervous system, today announced that ... officer, will present at the 33 rd annual ... place at 3:00 p.m. PST on Tuesday, January 13, ... San Francisco, Calif. About ...
(Date:12/19/2014)... 19, 2014 Bina Technologies, Inc. (Bina, ... they have been acquired by Roche (SIX: RO, ROG; ... held company that provides a big data platform for ... data for the academic and translational research markets.  Bina ... will continue to focus on development of their innovative ...
Breaking Biology Technology:Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... for functional food partners and market entrance, ... Neptune Technologies &,Bioressources Inc. ("Neptune") (NASDAQ.NEPT - ... has been determined to be,safe as a ... for the,commercialization of NKO(R) incorporated into different ...
... after biological olfaction, the challenge has been to generate ... complexity to detect odors in the real world. A ... with exact chemical precision and reproducibility. , In a ... PLoS Biology, Joel White, Mary AtKisson, John Kauer and ...
... /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), a ... discussing its,financial results for the fourth quarter and year ended December ... 2008 at 11:00 AM ET (8:00 ... Dial information is as follows: ...
Cached Biology Technology:Neptune Technologies receives GRAS notification in the United States 2Neptune Technologies receives GRAS notification in the United States 3Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast 2
(Date:12/22/2014)... 22, 2014 Research and Markets ... addition of the "The Global Watermarking ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... overview of the global digital media watermarking ... and monitor piracy by securely and invisibly ...
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first ... post-password and Internet of Things era, today announced the ... venture round was led by Metamorphic Ventures with participation ... Partners, VegasTechFund, and others.  LaunchKey has raised $4 million ... expand its team and bring LaunchKey to market in ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... sodium-retaining hormone in African Americans known to potentially cause ... of a study in the September issue of Experimental ... Temple Universitys College of Health Professions. The hormone, ... too much of it can contribute to the development ...
... may hold vital clues about how pancreatic cancer and diabetes ... access journal BMC Medicine, women with a history of gestational ... in life. The research team drawn from the US ... 37,000 mothers who gave birth between 1964 and 1976 in ...
... for our new disease problems, a far more cost ... in the places where they often commingle: in wildlife ... from the Wildlife Conservation Society (WCS) and the United ... issue of the prestigious Journal of Wildlife Diseases. ...
Cached Biology News:Understanding hypertension in African Americans proves elusive 2Emerging (disease) markets 2
...
Request Info...
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
The FliTrx Panning Kit is designed to simplify panning for protein-protein interactions with the FliTrx Random Peptide Display Library or the pFliTrx Peptide Display Vector....
Biology Products: